Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program

Published 14/11/2022, 18:02
© Reuters.  Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program
STOK
-

Benzinga -

  • Stoke Therapeutics Inc (NASDAQ: STOK) announced data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.
  • Today's results come almost a year after Stoke touted its first-in-human data for STK-001.
  • In addition to positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data, median reductions in seizure frequency were observed among patients who were treated with multiple doses of STK-001 (20mg, 30mg and 45mg).
  • In a subgroup of six patients examined at the highest dose (45mg) so far — who had all received three doses — Stoke observed a median 55% reduction in convulsive seizure frequency.
  • The reduction was seen between four weeks after patients received their first 45 mg dose and three months after receiving their third dose. They were among a total of 55 patients who had received at least one drug dose at any level.
  • The 20 and 30 mg doses performed numerically worse than the 45 mg in Monday’s data cut. In four patients who took three 20 mg doses, Stoke saw a median 41% reduction from baseline, while in 17 patients at the three-dose 30 mg level, researchers saw only a 20% median reduction.
  • Stoke had approximately $252.2 million in cash, cash equivalents, marketable securities, and restricted cash, which is anticipated to fund operations into 2025.
  • STOK reported a widened net loss for Q3 of $(26.1) million, or $(0.66) per share, versus $(22.6) million, or $(0.61) per share a year-ago.
  • Price Action: STOK shares are down 26.10% at $9.23 on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.